

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Guideline scope

Glaucoma: diagnosis and management (update)

This guideline will update the NICE guideline on glaucoma: diagnosis and management (NG81).

The guideline will be developed using the methods and processes outlined in [developing NICE guidelines: the manual](#).

This guideline will also be used to update the [NICE quality standard for serious eye disorders](#).

1 Why the update is needed

New evidence that could affect recommendations was identified through the surveillance process. Topic experts, including those who helped to develop the existing guideline, advised NICE on whether areas should be updated or new areas added. Full details are set out in the [surveillance review decision](#).

Why the guideline is needed

Please see the [original scope for NG81](#).

2 Who the guideline is for

This guideline is for:

- people using services, families and carers and the public
- optometrists
- ophthalmologists
- orthoptists
- pharmacists
- nurses

- general practitioners.

It may also be relevant for:

- commissioners of services.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#) and [Northern Ireland Executive](#).

Equality considerations

An equality impact assessment has been completed for this guideline update.

The assessment:

- lists equality issues identified, and how they have been addressed
- explains why any groups are excluded from the scope.

3 What the updated guideline will cover

3.1 *Who is the focus?*

Groups that will be covered

- Adults with chronic open angle glaucoma (COAG).
- Adults with ocular hypertension (OHT)
- Adults with COAG or OHT associated with pseudoexfoliation or pigment dispersion.

Groups that will not be covered

- Children and young people under 18 years.
- People with secondary glaucoma, for example, neovascular or uveitic glaucoma.
- People with, or at risk of, primary or secondary angle closure glaucoma.
- People with primary congenital, infantile or childhood glaucoma.

3.2 Settings

Settings that will be covered

- All settings in which NHS-funded healthcare is provided.

3.3 Activities, services or aspects of care

Key areas that will be covered in this update

We will look at evidence in the areas below when developing this update. We will consider making new recommendations or updating existing recommendations in these areas only.

- 1 Treatment
 - Treatment for people with OHT.
 - Treatment for people with COAG.

Proposed outline for the guideline

| Area in the guideline | What NICE plans to do |
|---|---|
| 1.1 Case finding | No evidence review: retain recommendations from existing guideline |
| 1.2 Diagnosis | No evidence review: retain recommendations from existing guideline |
| 1.3 Standard practice for all assessments | No evidence review: retain recommendations from existing guideline |
| 1.4 Reassessment | No evidence review: retain recommendations from existing guideline |
| 1.5 Treatment | Review evidence: update existing recommendations as needed, on treatment for ocular hypertension (recommendations 1.5.3 and 1.5.5 to 1.5.7) and chronic open angle glaucoma (recommendations 1.5.10, 1.5.12, 1.5.14 to 1.5.16 and 1.5.18 to 1.5.20) |
| 1.6 Organisation of care | No evidence review: retain recommendations from existing guideline |
| 1.7 Providing information | No evidence review: retain recommendations from existing guideline |

Recommendations in areas that are being retained from the existing guideline may be edited to ensure that they meet current editorial standards and reflect the current policy and practice context.

Areas that will not be covered by the guideline.

- 1 Population-based screening programmes for glaucoma.

3.4 Economic aspects

We will take economic aspects into account when making recommendations. The health technology report that triggered this update provides details of an economic model relating to this review question. This economic analysis and any other relevant economic reviews can be used to inform the committee's decision making and no further economic modelling is required. We will review

the economic evidence and carry out economic analyses, using an NHS perspective, as appropriate.

3.5 Key issues and draft questions

While writing the scope for this updated guideline, we have identified the following draft review question:

- 1 Treatment
 - 1.1 What is the effectiveness and cost-effectiveness of selective laser trabeculoplasty as a first-line treatment compared with intraocular pressure-lowering eyedrops for OHT or COAG in adults?

3.6 PICO table for the review question

| | |
|--------------|--|
| Population | Adults with chronic open angle glaucoma or ocular hypertension |
| Intervention | Selective laser trabeculoplasty |
| Comparison | Intraocular pressure-lowering eyedrops alone |
| Outcome | <p>Critical outcomes:</p> <ul style="list-style-type: none"> • Intraocular pressure level • Glaucomatous visual field loss • Normal visual field to visual field defect • Progression of glaucomatous visual field defect • Vision loss • Health-related quality of life • Adverse events <p>Important outcomes:</p> <ul style="list-style-type: none"> • Optic nerve head damage • Progression of optic nerve head damage • Normal or suspicious-to-abnormal optic nerve head • Treatment adherence • Treatment discontinuation |

4 NICE quality standards and NICE Pathways

4.1 NICE quality standards

NICE quality standards that may need to be revised or updated when this guideline is published

- [Serious eye disorders](#) (2019) NICE quality standard QS180

4.2 *NICE Pathways*

When this guideline is published, we will update the existing [NICE Pathway on glaucoma](#). NICE Pathways bring together everything NICE has said on a topic in an interactive flowchart.

5 Further information

This is the final scope.

The guideline is expected to be published: January 2022

You can follow [progress of the guideline](#).

Our website has information about [how NICE guidelines are developed](#).

© NICE 2021. All rights reserved. Subject to [Notice of rights](#).